GSK1605786A
Sponsors
GlaxoSmithKline
Conditions
Crohn's Disease
Phase 3
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
CompletedNCT01277666
Start: 2010-12-20End: 2013-07-11Updated: 2017-09-19
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
TerminatedNCT01316939
Start: 2011-05-09End: 2013-10-23Updated: 2017-09-07
Open-Label Extension Study of GSK1605786A
TerminatedNCT01318993
Start: 2011-04-01End: 2013-10-29Updated: 2017-09-14
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
TerminatedNCT01536418
Start: 2011-11-11End: 2013-10-17Updated: 2018-01-29